Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;42(6):1581-8.
doi: 10.1161/STROKEAHA.110.607994. Epub 2011 Apr 14.

MRI using ferumoxytol improves the visualization of central nervous system vascular malformations

Edit Dósa  1 , Suchita Tuladhar, Leslie L Muldoon, Bronwyn E Hamilton, William D Rooney, Edward A Neuwelt
Affiliations

MRI using ferumoxytol improves the visualization of central nervous system vascular malformations

Edit Dósa et al. Stroke. 2011 Jun.

Abstract

Background and purpose: Central nervous system vascular malformations (VMs) result from abnormal vasculo- and/or angiogenesis. Cavernomas and arteriovenous malformations are also sites of active inflammation. The aim of this study was to determine whether MRI detection of VMs can be improved by administration of ferumoxytol iron oxide nanoparticle, which acts as a blood pool agent at early time points and an inflammatory marker when taken up by tissue macrophages.

Methods: Nineteen patients (11 men, 8 women; mean age, 47.5 years) with central nervous system VMs underwent 3-T MRI both with gadoteridol and ferumoxytol. The ferumoxytol-induced signal changes on the T1-, T2-, and susceptibility-weighted images were analyzed at 25 minutes (range, 21 to 30 minutes) and 24 hours (range, 22 to 27 hours).

Results: Thirty-five lesions (capillary telangiectasia, n=6; cavernoma, n=21; developmental venous anomaly, n=7; arteriovenous malformation, n=1) were seen on the pre- and postgadoteridol images. The postferumoxytol susceptibility-weighted sequences revealed 5 additional VMs (3 capillary telangiectasias, 2 cavernomas) and demonstrated further tributary veins in all patients with developmental venous anomalies. The 24-hour T1 and T2 ferumoxytol-related signal abnormalities were inconsistent among patients and within VM types. No additional area of T1 or T2 enhancement was noted with ferumoxytol compared with gadoteridol in any lesion.

Conclusions: Our findings indicate that the blood pool agent ferumoxytol provides important information about the number and true extent of VMs on the susceptibility-weighted MRI. The use of ferumoxytol as a macrophage imaging agent in the visualization of inflammatory cells within and around the lesions warrants further investigation.

PubMed Disclaimer

Conflict of interest statement

Disclosures: AMAG Pharmaceuticals, Inc. provided the study drug ferumoxytol free of charge. OHSU has received a sponsored research agreement from AMAG to conduct clinical trials of MRI with ferumoxytol. None of the authors has financial interest in this agent or in its developer AMAG.

Figures

Figure 1
Figure 1. Capillary telangiectasia
A–C, Axial T1- (A), T2- (B), and susceptibility-weighted images (C) obtained before, after gadoteridol, 25 minutes, and 24 hours after ferumoxytol administration. The gadoteridol and the 24-hour ferumoxytol T1-weighted MRI show a faint enhancing lesion in the pons (arrow). The capillary telangiectasia is isointense on the T2-weighted ferumoxytol images at 24 hours. The lesion demonstrates prominent signal loss on the susceptibility-weighted ferumoxytol scans.
Figure 2
Figure 2. Cavernoma and capillary telangiectasia
A–C, Axial T1- (A), T2- (B), and susceptibility-weighted images (C) obtained before, after gadoteridol, 25 minutes, and 24 hours after ferumoxytol administration. The gadoteridol MRI shows enhancing lesions: a capillary telangiectasia (arrow) and a cavernoma (arrowhead) in the mesencephalon. The capillary telangiectasia is hyperintense at 25 minutes and hypointense at 24 hours on the T1-weighted images. The cavernoma, which has a T1 iso-, T2 hyperintense core and a T2 hypointense rim on the precontrast images, shows signal increase at 25 minutes and mixed ferumoxytol-related signal changes at 24 hours on the T1-weighted scans. Both lesions demonstrate signal loss on the T2- and susceptibility-weighted ferumoxytol images.
Figure 3
Figure 3. Susceptibility-weighted images of patient 6, 7, and 9
A–C, Axial susceptibility-weighted images of patient 6 (A), 7 (B), and 9 (C) obtained before and 24 hours after ferumoxytol administration. A, The ferumoxytol MRI shows a small capillary telangiectasia in the mesencephalon (arrow), while the precontrast image does not. Areas of decreased signal intensity are observed within the left temporal lobe tumor (arrowheads) 24 hours after ferumoxytol administration. B, The ferumoxytol MRI shows a capillary telangiectasia in the right basal ganglia (arrow), while the precontrast image does not. C, The ferumoxytol MRI shows a small cavernoma in the left anterior frontal lobe (arrow), while the precontrast image does not.
Figure 4
Figure 4. Developmental venous anomaly
A–B, Axial susceptibility-weighted images obtained before (A) and 25 minutes after ferumoxytol administration (B). Albeit the left cerebellar lesion is visible on both the pre- and post-ferumoxytol susceptibility-weighted images, but the ferumoxytol scan demonstrates additional tributary veins (rectangle) compared with the precontrast sequence.
Figure 5
Figure 5. Spinal cord arteriovenous malformation
A–D, Sagittal T1- (A), T2-(B), and T2*-weighted images (C) obtained before and T2*-weighted images obtained 25 minutes after ferumoxytol administration (D). The T2-weighted image shows abnormally increased intrinsic cord signal. Dorsal flow voids are visible (arrows). The abnormal tangle of blood vessels on the spinal cord is hypointense with ferumoxytol on the T2*-weighted images (arrowheads).
See this image and copyright information in PMC

References

    1. Brown RD, Jr, Flemming KD, Meyer FB, Cloft HJ, Pollock BE, Link ML. Natural history, evaluation, and management of intracranial vascular malformations. Mayo Clin Proc. 2005;80:269–281. Review. - PubMed
    1. Krings T, Lasjaunias PL, Hans FJ, Mull M, Nijenhuis RJ, Alvarez H, Backes WH, Reinges MH, Rodesch G, Gilsbach JM, Thron AK. Imaging in spinal vascular disease. Neuroimaging Clin N Am. 2007;17:57–72. Review. - PubMed
    1. Gault J, Sarin H, Awadallah NA, Shenkar R, Awad IA. Pathobiology of human cerebrovascular malformations: basic mechanisms and clinical relevance. Neurosurgery. 2004;55:1–16. discussion 16–17. Review. - PubMed
    1. Leblanc GG, Golanov E, Awad IA, Young WL. Biology of Vascular Malformations of the Brain NINDS Workshop Collaborators. Biology of vascular malformations of the brain. Stroke. 2009;40:e694–702. Review. - PMC - PubMed
    1. Sehgal V, Delproposto Z, Haacke EM, Tong KA, Wycliffe N, Kido DK, Xu Y, Neelavalli J, Haddar D, Reichenbach JR. Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging. 2005;22:439–450. Review. - PubMed

Publication types